Navigation Links
Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth

Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements about Columbia Laboratories, Inc.'s expectations regarding the Company's strategic direction, prospects and future results, which statements are indicated by the words "will," "plan," "expect" and similar expressions. Such forward-looking statements are subject to certain risks and uncertainties; actual results may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. Factors that might cause future results to differ include, but are not limited to, the following: the successful marketing of CRINONE(R) 8% (progesterone gel), PROCHIEVE(R) 8%(progesterone gel), PROCHIEVE 4% (progesterone gel), and STRIANT(R) (testosterone buccal tablet) in the U.S.; the timely and successful development of new products, including the clinical and regulatory path for possible development of PROCHIEVE 8% for the prevention of preterm birth; the timely and successful completion of clinical studies; the impact of competitive products and pricing; competitive economic and regulatory factors in the pharmaceutical and healthcare industry; general economic conditions; and other risks and uncertainties that may be detailed, from time-to-time, in Columbia's reports filed with the Securities and Exchange Commission. Columbia Laboratories undertakes no obligation to publicly update any forward-looking statements.

CRINONE(R), PROCHIEVE(R) and STRIANT(R) are registered trademarks of Columbia Laboratories, Inc.

Contact

Columbia Laboratories, Inc.
James A. Meer, 973-486-8860
Senior Vice President, CFO & Treasurer
or
Rx Communications, LLC
Melody A. Carey, 917-322-2571
Co-President


'"/>




Page: 1 2 3

Related medicine technology :

1. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
2. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
3. Northfield Laboratories Reports Results of Pivotal Phase III Trauma Study
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
5. Northfield Laboratories Investor Update
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... , Aug. 27, 2015  Eli Lilly and ... Stanley Global Healthcare Conference on Thursday, September 17, 2015. ... president of Lilly Oncology and Richard Gaynor , ... affairs for Lilly Oncology, will participate in a fireside ... A live audio webcast will be available on ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic Informed Consent for ... 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact about electronic informed ... , Clinical trial sites can now use audio, video and interactivity to ...
(Date:8/29/2015)... PITTSBURGH, PA (PRWEB) , ... August 29, 2015 ... ... 1996," said one of two inventors from Miller Place, N.Y. "I specialize in ... pain and discomfort. In addition, it can be used for additional muscle dysfunction ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made ... the lives of patients, according to a newly published report. Surviving Mesothelioma has ... full article. , The authors of the new paper focus on several ...
(Date:8/29/2015)... ... 29, 2015 , ... Brands like Toppik , Eau Thermale Avene and ... “Before, a threshold of $49.00 was required to qualify for free standard shipping,” said ... standard shipping for customers regardless of the item’s selling price.” , With competitive pricing ...
(Date:8/29/2015)... ... 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops designed for ... unique footage that users can shrink and stretch in the Final Cut Pro X ... customize color, brightness, scale, speed, range, and flare attributes with intuitive controls found in ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2
... the threats to themselves and relatives, study says , , FRIDAY, ... families in which some members have BRCA1 or 2 gene ... cancer -- typically avoid genetic counseling or testing, a new ... they,re less likely than women to pass on the information ...
... LOUIS, Feb. 27 Stereotaxis, Inc. (Nasdaq: ... Food and Drug Administration approved for marketing the NAVISTAR(R) ... Inc, a Johnson & Johnson company. The NAVISTAR(R) RMT ... Navigation System for mapping and radiofrequency (RF) ablation to ...
... N.J., Feb. 27 The Board of Directors of Schering-Plough ... dividend of 6.5 cents per common share. Payment will ... at the close of business on May 1, 2009. ... outstanding. The Board of Directors today also declared a quarterly ...
... of Long Term Care Workforce Put at Risk by FY ... LTC Sector to U.S. Economy, Jobs Base, Tax RevenueWASHINGTON, Feb. ... the nation,s long term care sector is a key driver ... revenue, state and national long term care leaders expressed alarm ...
... following is a statement by Robert Greenstein, Executive Director ... budget represents a bold and courageous proposal to make ... problems of our time -- a broken health care ... and other national needs.Particularly courageous are several proposals that ...
... FindingsNEWPORT NEWS, Va., Feb. 27 Women facing a ... the same or opposite breast with further testing using ... in the February 2009 "American Journal of Surgery." BSGI ... same or opposite breast in 10.9 percent of newly ...
Cached Medicine News:Health News:Men With BRCA Gene Mutations Unaware of Cancer Risks 2Health News:Men With BRCA Gene Mutations Unaware of Cancer Risks 3Health News:Stereotaxis Announces FDA Approval of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter 2Health News:National, State Long Term Care Leaders Express Concern That FY 2010 Medicare Cuts Undermine, Contradict Intent of Economic Stimulus Law 2Health News:National, State Long Term Care Leaders Express Concern That FY 2010 Medicare Cuts Undermine, Contradict Intent of Economic Stimulus Law 3Health News:Statement by Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on the President's 2010 Budget Proposal 2Health News:Statement by Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on the President's 2010 Budget Proposal 3Health News:Statement by Robert Greenstein, Executive Director, Center on Budget and Policy Priorities, on the President's 2010 Budget Proposal 4Health News:Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients 2Health News:Breast-Specific Gamma Imaging (BSGI) Uncovers Additional Breast Cancer in Newly Diagnosed Breast Cancer Patients 3
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
... Utilizing the most complex grinding ... accurate trial lens, are specifically ... quality and precision as the ... marco RT-300 refractor. Marco custom ...
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Medicine Products: